STOCK TITAN

Edesa Biotech (EDSA) CEO awarded 1,159 RSUs and reports updated share holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Nijhawan Pardeep reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported an equity award and updated share holdings. He received a grant of 1,159 restricted share units that vested in full upon grant at a price of $0.0000 per share under the company’s 2019 Equity Incentive Compensation Plan, increasing his direct holdings to 632,550 common shares following the award.

Indirect holdings are reported through several entities: 402,702 common shares held by Pardeep Nijhawan Medicine Professional Corporation, 53,104 shares held by 1968160 Ontario Inc., 32,013 shares held by The Digestive Health Clinic Inc., and 32,609 shares held by The New Nijhawan Family Trust 2015. The reporting person disclaims beneficial ownership of these indirect securities except to the extent of his pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Nijhawan Pardeep
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Common Shares 1,159 $0.00 --
holding Common Shares -- -- --
holding Common Shares -- -- --
holding Common Shares -- -- --
holding Common Shares -- -- --
Holdings After Transaction: Common Shares — 632,550 shares (Direct, null); Common Shares — 402,702 shares (Indirect, Held by Pardeep Nijhawan Medicine Professional Corporation)
Footnotes (1)
  1. Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
RSU grant 1,159 common shares Restricted share units vested in full upon grant at $0.0000 per share
Direct holdings after grant 632,550 common shares Shares directly held by reporting person following RSU award
Indirect holdings (Medicine Corp.) 402,702 common shares Held by Pardeep Nijhawan Medicine Professional Corporation
Indirect holdings (1968160 Ontario Inc.) 53,104 common shares Held by 1968160 Ontario Inc.
Indirect holdings (Digestive Health Clinic) 32,013 common shares Held by The Digestive Health Clinic Inc.
Indirect holdings (Family Trust) 32,609 common shares Held by The New Nijhawan Family Trust 2015
Grant price per share $0.0000 per share Price for restricted share units granted under 2019 plan
restricted share units financial
"Reflects a grant of restricted share units, which vested in full upon grant"
Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.
2019 Equity Incentive Compensation Plan financial
"vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan"
pecuniary interest financial
"disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein"
beneficial ownership financial
"shall not be deemed an admission of beneficial ownership of all of the reported shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
co-trustee financial
"Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015"
Section 16 regulatory
"for purposes of Section 16 or for any other purpose"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Nijhawan Pardeep

(Last)(First)(Middle)
C/O EDESA BIOTECH INC.
100 SPY COURT

(Street)
MARKHAML3R 5H6

(City)(State)(Zip)

ONTARIO, CANADA

(Country)
2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares05/01/2026A1,159(1)A$0(1)632,550D
Common Shares402,702IHeld by Pardeep Nijhawan Medicine Professional Corporation(2)
Common Shares32,609IHeld by The New Nijhawan Family Trust 2015(3)
Common Shares32,013IHeld by The Digestive Health Clinic Inc.(2)
Common Shares53,104IHeld by 1968160Ontario Inc.(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.
2. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
3. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
/s/ Peter J. Weiler, Attorney-in-Fact for Pardeep Nijhawan05/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Edesa Biotech (EDSA) CEO Pardeep Nijhawan report in this Form 4?

He reported an equity compensation award and updated share holdings. The filing shows a grant of 1,159 restricted share units and updated direct and indirect ownership positions across several related entities and a family trust.

How many Edesa Biotech (EDSA) shares did the CEO receive in this grant?

He received 1,159 restricted share units of common shares. These units vested in full upon grant and were issued at a price of $0.0000 per share under Edesa Biotech’s 2019 Equity Incentive Compensation Plan.

What is Pardeep Nijhawan’s direct Edesa Biotech (EDSA) share ownership after the grant?

After the grant, he directly holds 632,550 common shares. This figure reflects his position following the award of 1,159 restricted share units that vested immediately under the company’s 2019 equity incentive compensation plan.

Which entities hold Edesa Biotech (EDSA) shares associated with the CEO?

Shares are held by several entities: Pardeep Nijhawan Medicine Professional Corporation, The Digestive Health Clinic Inc., 1968160 Ontario Inc., and The New Nijhawan Family Trust 2015, each reporting separate indirect holdings of Edesa Biotech common shares.

Does the Edesa Biotech (EDSA) CEO claim full beneficial ownership of the indirect shares?

No. The filing states he disclaims beneficial ownership of the indirect shares except to the extent of his pecuniary interest, including positions held through corporations and a family trust, for Section 16 and other purposes.